| Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories |
The
following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable
segment for the years ended December 31, 2025 and 2024:
Schedule
of Reportable Segment Profit and Loss, Including Significant Expense Categories
| |
|
2025 |
|
|
2024 |
|
| |
|
Year
ended December 31, |
|
| |
|
2025 |
|
|
2024 |
|
| Preclinical, clinical trial
and other costs |
|
$ |
6,240,583 |
|
|
$ |
5,450,963 |
|
| Research and development
personnel expense(1) |
|
|
1,569,754 |
|
|
|
1,818,183 |
|
| General and administrative
personnel expense(2) |
|
|
2,786,832 |
|
|
|
1,981,756 |
|
| Administrative and facilities
expense(3) |
|
|
3,391,336 |
|
|
|
2,800,304 |
|
| Other income, net |
|
|
(424,671 |
) |
|
|
(201,088 |
) |
| Total |
|
$ |
13,563,834 |
|
|
$ |
11,850,118 |
|
| Net Loss |
|
$ |
13,563,834 |
|
|
$ |
11,850,118 |
|
| (1) |
|
Research
and development personnel costs include employee stock-based compensation expense of $192,630 and $169,414 for the year ended December
31, 2025 and 2024, respectively. |
| (2) |
|
General
and administrative personnel costs include employee stock-based compensation expense of $508,644 and $186,925 for the year ended
December 31, 2025 and 2024, respectively, and are net of reimbursements received from CorLyst, LLC. |
| (3) |
|
Administrative
& facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel,
and other administrative costs. |
|